Valuation: Monte Rosa Therapeutics, Inc.

Market Cap 831M 739M 685M 623M 1.18B 78.86B 1.19B 8.23B 3.23B 41.15B 3.12B 3.05B 131B P/E 2026 *
-6.66x
P/E 2027 * -5.23x
Enterprise Value 513M 456M 423M 385M 726M 48.71B 738M 5.08B 1.99B 25.42B 1.93B 1.89B 81.04B EV / Sales 2026 *
7.51x
EV / Sales 2027 * 6.19x
Free-Float
99.44%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Monte Rosa Therapeutics, Inc.

1 day-3.75%
1 week-5.44%
Current month-18.36%
1 month-22.70%
3 months-60.34%
6 months-50.76%
Current year-37.88%
1 week 9.7
Extreme 9.705
10.63
1 month 9.68
Extreme 9.68
12.73
Current year 9.68
Extreme 9.68
25.77
1 year 8.94
Extreme 8.9431
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
27.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2020
Chief Tech/Sci/R&D Officer - 17/03/2026
Chief Operating Officer 54 01/03/2021
Director TitleAgeSince
Director/Board Member 55 01/01/2020
Director/Board Member 49 01/04/2020
Director/Board Member 57 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
5/10/26 Sell

Controller/Auditor

-13 0.0000%
16/7/26 Sell

Chief Executive Officer

-9,500 0.0112%
15/7/26 Exercice

Chief Operating Officer

13,053 0.0155%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%-5.44%-3.08%+142.89% 831M
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -1.87%-0.86%+40.66%+99.18% 37.32B
Weighted average by Cap. -2.20%-0.51%+44.14%+96.64%

Financials

2026 *2027 *
Net sales 68.35M 60.75M 56.31M 51.23M 96.68M 6.49B 98.23M 677M 265M 3.38B 257M 251M 10.79B 64.61M 57.43M 53.23M 48.43M 91.39M 6.13B 92.85M 640M 251M 3.2B 242M 237M 10.2B
Net income -148M -131M -122M -111M -209M -14.03B -213M -1.46B -574M -7.32B -555M -543M -23.35B -196M -175M -162M -147M -278M -18.65B -282M -1.95B -763M -9.73B -737M -722M -31.02B
Net Debt -318M -282M -262M -238M -449M -30.15B -457M -3.15B -1.23B -15.73B -1.19B -1.17B -50.15B -431M -383M -355M -323M -610M -40.9B -619M -4.27B -1.67B -21.34B -1.62B -1.58B -68.03B
Projected Income Statement - Annual - Monte Rosa Therapeutics, Inc.
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
173
Date Price Change Volume
16/10/26 USD 9.740 -3.75% 885,433
15/10/26 USD 10.12 +2.85% 1,543,915
14/10/26 USD 9.840 -0.51% 1,092,893
13/10/26 USD 9.890 -5.99% 2,714,008
12/10/26 USD 10.52 +2.14% 2,094,587
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Monte Rosa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
9.740USD
Average target price
26.88USD
Spread / Average Target
+175.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Monte Rosa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. GLUE Stock